1012054-59-9 | CUDC-101

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$47.00	$33.00
5mg	95%	in stock	$59.00	$41.00
10mg	95%	in stock	$102.00	$71.00
25mg	95%	in stock	$138.00	$97.00
50mg	95%	in stock	$255.00	$179.00
100mg	95%	in stock	$434.00	$304.00
250mg	95%	in stock	$936.00	$655.00
1g	95%	in stock	$2,213.00	$1,549.00

Description

• Catalog Number: AA04921
• Chemical Name: CUDC-101
• CAS Number: 1012054-59-9
• Molecular Formula: C24H26N4O4
• Molecular Weight: 434.4876
• MDL Number: MFCD15528940
• SMILES: ONC(=O)CCCCCCOc1cc2c(ncnc2cc1OC)Nc1cccc(c1)C#C

Computed Properties

• Complexity: 624
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 12
• XLogP3: 4

Upstream Synthesis Route

CUDC-101, a potent multi-targeted kinase inhibitor, has found significant application in chemical synthesis due to its versatile properties. This compound, known for its ability to inhibit several key enzymes involved in cellular processes, serves as a valuable tool in the development of novel molecules and therapeutic compounds.In chemical synthesis, CUDC-101 enables chemists to target specific pathways and manipulate cellular functions, making it a crucial component in the creation of new pharmaceuticals, agrochemicals, and other organic compounds. By selectively blocking various kinase enzymes, this compound facilitates the design and production of compounds with desired biological activities and pharmacological properties.Moreover, the multi-targeted nature of CUDC-101 allows for diverse applications in chemical synthesis, providing researchers with a flexible platform to explore different pathways and mechanisms of action. Its efficacy in modulating various cellular processes makes it an indispensable resource in the discovery and development of biologically active compounds for a wide range of applications.Overall, CUDC-101 plays a vital role in advancing chemical synthesis by serving as a powerful tool for researchers to explore new pathways, develop innovative compounds, and ultimately contribute to the growth and diversification of the field.

Literature

• A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20150401

• Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20141001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

• Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.

  Archives of pharmacal research 20120201

• Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

  British journal of cancer 20111108

• Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

  Journal of biomedicine & biotechnology 20110101

• CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

  Cancer research 20100501

• Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

  Journal of medicinal chemistry 20100311